IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$76.48 USD
+1.62 (2.16%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $76.46 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ITCI 76.48 +1.62(2.16%)
Will ITCI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ITCI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ITCI
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High?
ITCI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Other News for ITCI
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Intra-Cellular price target raised by $6 at Needham, here's why
A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies
Buy Rating Affirmed for Intra-Cellular Therapies with Caplyta Poised for Blockbuster Success
Intra-Cellular just downgraded at UBS, here's why